RTP Mobile Logo
Challenging Cases in Multiple Myeloma: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Released August 2014

Video excerpts from the fifth in a series of 6 integrated symposia held at the 2014 ONS Annual Congress. Featuring perspectives from Dr P Leif Bergsagel, Ms Charise L Gleason, Ms Tiffany Richards and Dr Jeffrey L Wolf. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).

    OVERVIEW OF ACTIVITY
    MM accounts for approximately 10% of all hematologic cancer cases and carries with it the worst death/new cases ratio with approximately 75% of patients with newly diagnosed MM dying of the disease. Although those with asymptomatic smoldering myeloma may be observed, the course for advanced myeloma is uniformly aggressive. However, the introduction of novel proteasome inhibitors and immunomodulatory agents has improved outcomes and allowed patients to experience longer periods of remission, effectively transforming standard treatment for patients with newly diagnosed and relapsed/refractory MM.

    These video proceedings from the fifth part of a 6-part integrated CNE curriculum originally held at the 2014 ONS Annual Congress feature discussions with leading hematologic investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM.

    LEARNING OBJECTIVES

    • Compare and contrast the benefits and risks of evidence-based induction regimens.
    • Recognize the side effects commonly associated with available proteasome inhibitors and immunomodulatory drugs, and develop strategies to avert or mitigate these toxicities.
    • Customize the use of maintenance therapeutic approaches in the post-transplant and nontransplant settings based on patient- and disease-related factors, including cytogenetic profile.
    • Effectively integrate the recently FDA-approved agents carfilzomib and pomalidomide into the nonresearch care of patients with MM.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with MM to improve clinical and quality-of-life outcomes.
    • Recall ongoing trials of investigational approaches and treatment strategies in MM, and refer patients and obtain consent for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. Participants should read the learning objectives and faculty disclosures and watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    P Leif Bergsagel, MD
    Grohne Professor of Therapeutics in Cancer Research
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Astellas, Onyx Pharmaceuticals Inc, Sanofi; Contracted Research: Novartis Pharmaceuticals Corporation.

    Charise L Gleason, MSN, ANP-C, AOCNP
    Nurse Practitioner
    The Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Consulting Agreement: Celgene Corporation.

    Tiffany Richards, MS, ANP-BC, AOCNP
    Nurse Practitioner
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Celgene Corporation, Onyx Pharmaceuticals Inc.

    Jeffrey L Wolf, MD
    Professor of Medicine
    Director, Myeloma Program
    Division of Hematology/Oncology
    Blood and Marrow Transplantation
    University of California, San Francisco
    San Francisco, California

    Advisory Committee, Consulting Agreements and Speakers Bureau: Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):